Generic Name and Formulations:
Fluconazole 150mg; tabs.
150mg orally once.
Concomitant terfenadine at multiple doses of fluconazole ≥400mg. Concomitant drugs known to prolong the QT interval and metabolized by CYP3A4 (eg, cisapride, astemizole, erythromycin, pimozide, quinidine).
Proarrhythmic conditions. Renal or hepatic impairment. Elderly. Pregnancy (Cat.C). Nursing mothers.
See Contraindications. Risk of cardiotoxicity with erythromycin; avoid. Avoid concomitant voriconazole; if needed, monitor closely esp. when given within 24hrs after fluconazole. Potentiates warfarin, oral hypoglycemics, oral midazolam, tofacitinib, alfentanil, amitriptyline, nortriptyline, calcium channel blockers, losartan, saquinavir; adjust dose as necessary. May increase serum levels of phenytoin, theophylline, halofantrine, rifabutin, tacrolimus, sirolimus, vinca alkaloids, triazolam, methadone, NSAIDs, cyclosporine, zidovudine, sulfonylureas, carbamazepine. Concomitant celecoxib: reduce celecoxib dose by half. Thiazides increase fluconazole levels. Monitor levels and/or effects of cyclosporine, phenytoin, sulfonylureas, rifabutin, tacrolimus, theophylline, warfarin, prednisone. Increased risk of myopathy/rhabdomyolysis with concomitant HMG-CoA reductase inhibitors; closely monitor. Cimetidine (oral), rifampin may decrease fluconazole levels. Oral contraceptives: see full labeling. Avoid other hepatotoxic drugs. Caution with other drugs metabolized by CYP2C9 and CYP3A4 with a narrow therapeutic window.
Nausea, headache, rash, vomiting, abdominal pain, diarrhea, dizziness, seizures; hepatotoxicity; rare: exfoliative dermatitis, QT prolongation, Torsade de pointes.